The first successful T cell immunotherapy for advanced breast cancer
T cells in a woman with metastatic breast cancer eliminate her tumor, researchers report today (4 June) in nature medicine. This is the first time that advanced breast cancer has been successfully treated with t-cell immunotherapy.
Steven Rosenberg, an oncologist and immunologist at the national cancer institute (NCI), told NPR, "We're looking for a treatment that can be widely used in patients with common cancers - an immunotherapy." The results suggest that this type of treatment may be possible for other types of solid tumors, including the colon, rectum, and pancreas.
To develop the treatment, Rosenberg and his colleagues used full exome and RNA sequencing to identify point mutations in a patient's breast tumor genome, then isolated tumor-infiltrating lymphocytes from the tumor and determined which genes were responsive to mutations in SLC3A2., ECPAS, CADPS2 and CTSB, were present in her tumor. The researchers then gave patients about 90 billion tumor-infiltrating lymphocytes that target four mutated genes. In addition, she was treated with antibodies against programmed cell death protein-1 two days before the T cell metastasis and received antibody infusion three, six, and nine weeks later. Her tumor was gone.
The result is "an unprecedented response to this advanced breast cancer," Laszlo Radvanyi of the Ontario cancer institute in Toronto wrote in an accompanying Nature Medicine News& Views article.
But Rosenberg told NPR the treatment is not for everyone. Two other patients with breast cancer did not respond to the treatment. But the method has helped seven patients, including those with colon, liver or cervical cancer. "Ready for prime time today?" No," Rosenberg said." Can we do that in most patients today?" No, but," he said, "I think this is the most promising treatment being explored to address the treatment of metastatic common cancers."
"This is an illustrative case report that once again highlights the power of immunotherapy," Tom Mistily, director of the NCI cancer research center, who was not involved in the study, told Forbes." If confirmed in a larger study, it has the potential to further extend this t-cell therapy to a broader range of cancers."
Mouse IL2 Inducible T-Cell Kinase (ITK) ELISA Kit (DL-ITK-Mu): https://dldevelop.com/Research-reagent/dl-itk-mu.html
Human V-Set Domain Containing T-Cell Activation Inhibitor 1 (VTCN1) ELISA Kit (DL-VTCN1-Hu): https://dldevelop.com/Research-reagent/dl-vtcn1-hu.html
Steven Rosenberg, an oncologist and immunologist at the national cancer institute (NCI), told NPR, "We're looking for a treatment that can be widely used in patients with common cancers - an immunotherapy." The results suggest that this type of treatment may be possible for other types of solid tumors, including the colon, rectum, and pancreas.
To develop the treatment, Rosenberg and his colleagues used full exome and RNA sequencing to identify point mutations in a patient's breast tumor genome, then isolated tumor-infiltrating lymphocytes from the tumor and determined which genes were responsive to mutations in SLC3A2., ECPAS, CADPS2 and CTSB, were present in her tumor. The researchers then gave patients about 90 billion tumor-infiltrating lymphocytes that target four mutated genes. In addition, she was treated with antibodies against programmed cell death protein-1 two days before the T cell metastasis and received antibody infusion three, six, and nine weeks later. Her tumor was gone.
The result is "an unprecedented response to this advanced breast cancer," Laszlo Radvanyi of the Ontario cancer institute in Toronto wrote in an accompanying Nature Medicine News& Views article.
But Rosenberg told NPR the treatment is not for everyone. Two other patients with breast cancer did not respond to the treatment. But the method has helped seven patients, including those with colon, liver or cervical cancer. "Ready for prime time today?" No," Rosenberg said." Can we do that in most patients today?" No, but," he said, "I think this is the most promising treatment being explored to address the treatment of metastatic common cancers."
"This is an illustrative case report that once again highlights the power of immunotherapy," Tom Mistily, director of the NCI cancer research center, who was not involved in the study, told Forbes." If confirmed in a larger study, it has the potential to further extend this t-cell therapy to a broader range of cancers."
Mouse IL2 Inducible T-Cell Kinase (ITK) ELISA Kit (DL-ITK-Mu): https://dldevelop.com/Research-reagent/dl-itk-mu.html
Human V-Set Domain Containing T-Cell Activation Inhibitor 1 (VTCN1) ELISA Kit (DL-VTCN1-Hu): https://dldevelop.com/Research-reagent/dl-vtcn1-hu.html
